Nuvig Therapeutics

Person using a calculator
#Autoimmune disease #Financing #Immunomodulators #Nuvig Therapeutics #Phase II trial

Immunomodulatory therapeutics company raises $161m

Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases.  The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners.  There was also participation from… Read More

#Business & Investment #News